Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled Phase 2 clinical trial to investigate the safety and efficacy of SPT-2101 given as a single administration in the patients with Meniere's-disease

Next Previous
Search
Trial Profile

A randomized, placebo-controlled Phase 2 clinical trial to investigate the safety and efficacy of SPT-2101 given as a single administration in the patients with Meniere's-disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Dexamethasone
  • Indications Meniere's disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Sep 2024 According to a Spiral Therapeutics media release, additional results will be reported in the coming weeks.
    • 30 Sep 2024 According to a Spiral Therapeutics media release, company presented results at a breakfast meeting with key opinion leaders during the American Academy of Otolaryngology Annual Meeting 2024 in Miami, FL, on September 28th.
    • 30 Sep 2024 Results published in the Spiral Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top